Call Us:  +1.302.777.7774

CECON logo

Log in
Loading...
Show More
Add this resume to contact form Yes No
Back to Search Result GO

Pharmaceutical Medicinal Chemist Drug Development, Drug Formulations Expert

Technical Consultant #2370


Expertise

  • Discovery and development of novel human therapeutics for: Anti-infective, anti-inflammatory and neurodegenerative diseases.
  • Development of antibacterial clinical candidates, and the discovery of five preclinical candidates for Multiple Sclerosis, Arthritis and Spinal Muscular Atrophy.
  • Drug research and development from synthesis/purification, in-vitro, in-vivo (efficacy and pharmacokinetics) testing, dosing routs, formulation and the management of CROs to support pre-clinical testing.
  • Chemical analysis of pharmaceutical and nutraceuticals products.
  • Drug formulation and drug stability studies.
  • Design, synthesis and purification of drugs.
  • Drug development in the areas of inflammation, spinal muscular atrophy, multiple sclerosis and anti-bacterial.
  • Formulating drugs for stability, solubility and bioavailability studies. Designed protocols for IP, IV, ICV, IT and oral dosing studies.
  • Cross couplings, transition metal catalysts, formylation, Iodination and peptide coupling reactions
  • TLC, IR, 1H NMR, 13C NMR, 2D NMR, HPLC and LCMS.
  • HPLC and Flash chromatography.

Expert Witness Experience

  • All aspects of drug research and development.
  • Patent infringement, provided chemical analysis of disputed products.

Experience

Undisclosed Company, Independent Expert Witness Consultant, 2016 - Present

  • Provide professional consulting and expert witness services to the undisclosed client through legal counsel pertaining to patent infringement.
  • Coordinate and oversee the chemical analysis of the defendant's contested products.
  • Preparing expert reports regarding the infringement of contested products over the asserted claims.

Mylan Pharmaceuticals, Independent Expert Witness Consultant, 2016

  • Provided professional consulting and expert witness services to Mylan Inc. through legal counsel in connection with opposing ANDA patent infringement litigation in the area of pharmaceutical technology.
  • Prepared expert reports regarding the invalidity of Pfizer patents concerning the reformulation of one of their products.
  • Provided compelling arguments based on examples within the prior art, of why it would have been obvious to a person skilled in the art to at least try the formulation in the contested patents with a reasonable expectation of success.
  • Prepared reply reports in response to Plaintiff experts' responsive reports, reconfirmed presented arguments as well as highlighted Opponents experts' contradictions and misrepresentations of the prior art.
  • Participated in a 7 hour deposition.
  • Involved with the pre-trial preparation.

Salve Regina University, Newport RI, Professor, 2014 - Present

  • Responsible for teaching Organic Chemistry lab and lecture science classes.

Cemotics LLC, Providence, RI, Consultant, 2014 - 2016

Project: Biotech developing therapeutics for cancer and malaria

  • Developed Arysphosphonium Salts (APS) as anti-cancer agents. Responsibilities include design of novel compounds, development of screening cascade and medicinal chemistry lead optimization efforts.
  • Interacted with vendors to facilitate whole cell screening, toxicity, in vivo efficacy and ADME.
  • Developed a novel treatment for malaria that circumvents resistance, generation of preliminary data through outsourcing with vendors.

Paratek Pharmaceuticals, Boston, MA, Principal Scientist, 2002 - 2013

Principal Scientist and Project Coordinator, 2009 - 2013

  • Biotechnical development of tetracycline therapeutics for anti-infective, anti-inflammatory and neurodegenerative diseases.

Project Coordinator-Lab, 2009 - 2013

Project 1

  • Coordinated the efforts of the Spinal Muscular Atrophy (SMA) program in preclinical development.
  • Responsible for design and development of intrathecal (IT) and intracerebroventricular (ICV) continuous and bolus dosing protocols for mice, rat and monkey studies.
  • Designed and conducted stability studies and formulation studies for continuous dosing efficacy studies to be compatible with Alezet osmotic pumps.
  • Worked with cross-functional teams in cell-biology, pharmacology, process chemistry and vendors that supported in vivo efficacy studies, DMPK and GLP toxicity studies.
  • Responsible for synthesis of new compounds and lead optimization of medicinal chemistry efforts for SMA.
  • Outsourced and managed preclinical efficacy/PK testing of three compounds at multiple CROs to facilitate pre-clinical toxicity and further PK analysis of our clinical candidate in mice, rat and monkey.
  • Contributed to grant writing for NIH and FSMA grants.

Project 2

  • Developed a new antibacterial for bacterial resistant respiratory infections in cattle for Elanco.
  • Delivered an efficacious antibacterial compound for subcu bolus dosing which would not tissue stain.
  • Managed one direct reports.

Senior Scientist and Project Coordinator-Lab, 2006 - 2009

  • Worked on areas of anti-inflammation and functioned as the project coordinator for SMA.
  • Responsible for synthesis of new derivatives, lead optimization, analysis of results from outsourced and in house in vitro studies, whole cell, pharmacology and in vivo studies.
  • Worked with cross-functional teams in cell-biology, pharmacology, process chemistry as well as vendors that supported in vitro and in vivo efficacy studies.
  • Developed HPLC purification methods for large-scale (6" diameter column) epimer separation of novel tetracycline derivatives previously not possible.
  • Managed one direct reports.

Scientist II, 2003 - 2005

  • Discovered and developed novel tetracyclines for the treatment of multiple sclerosis (MS) in collaboration with Serono. Delivered three validated pre-clinical tetracycline leads for MS.
  • Developed formulation procedures that reduced tolerability issues when dosing IP and IV and enabled a wider therapeutic window with which to compare compounds in experimental autoimmune encephalomyelitis (EAE) mouse efficacy studies.
  • Responsible for synthesis of new derivatives, lead optimization and analysis of results from in vivo efficacy
  • Worked with cross-functional teams in cell-biology, pharmacology and process chemistry.
  • Built a micro reactor to developed an oxidation assay to elucidate the structure activity relationship for tetracycline oxidation/tissue staining, a potentially negative aspect of some tetracyclines. The assay's results correlated with tissue staining in vivo.

Scientist I, 2002 - 2003

  • Contributed to the development of pre-clinical candidates for hospital and community acquired severe bacterial infections.
  • Optimized synthetic methods and developed purification protocols for two key tetracycline intermediates on a 100g scale. This work removed a huge bottleneck in the production of tetracycline derivatives.
  • One lead compound is currently in phase III trials (Omadacycline) and a second has completed Phase I.

Eikos Inc., Franklin, MA, Scientist I, 2002

  • Oversee biotechnical and material science co development of anti malaria drugs and incorporation of carbon nanotubes into polymers.
  • Managed all aspects of chemistry at Eikos. Conducted Polymer production reactions using a 50L reactor.
  • Developed a solid phase organic synthesis protocol for the production of aminoquinoline antimalarials in support of an SBIR grant.
  • Managed three direct reports.

Brown University, Providence, RI, Graduate Researcher, Department of Chemistry, 1996 - 2002

  • Studied protease inhibitors and developed a novel enzymatic assay for screening catalysts for asymmetric reactions.
  • Optimized a novel class of protease inhibitors based on a cyclohexanone core
  • Developed a protocol for the synthesis of cyclohexanone-based protease inhibitors on solid support.
  • Designed and synthesized a 400-member library of these cyclohexanone inhibitors on solid support.
  • Developed an enzymatic assay for high-throughput screening of catalysts for asymmetric reactions.
  • Developed methodology to conduct assays in a 384 well format to assess inhibition constants for a library of peptidomimetic compounds against cathepsin B, plasmin, papain, trypsin, thrombin and kallikrein.
  • Monitored reactions by TLC, IR, 1H NMR, 13C NMR, and HPLC.
  • Purification by flash chromatography, crystallization, distillation, separation of diastereomers by HPLC and enantiomers by both chiral-GC and chiral-HPLC.
  • Analysis of final compounds 1H NMR, 13C NMR, 2D NMR and MS.
  • Proficient with enzymatic assays and jell electrophoresis.

Honors & Publications


Credentials

  • Computer skills: Microsoft word, Excel, PowerPoint, Photoshop

Awards

  • Excellence Award: Organic Chemistry by the American Polymer Society

Publications and Patents

  • Author and Co-Author of publications: Peer reviewed journals, posters and abstracts
  • Inventor and Co-Inventor, 9 patents: World, U.S., Canada (with focus to tetracycline compounds)

Education

  • Ph.D. Chemistry, Brown University, Providence, RI
  • B.S. Chemistry, Rhode Island College, Providence, RI
Back to Search Result GO

Login to your account

Username *
Password *
Remember Me